NCT01231737 is a Phase 2 clinical trial of prulifloxacin in Urinary Tract Infection, sponsored by University Of Perugia.

Who is sponsoring NCT01231737?

NCT01231737 is sponsored by University Of Perugia.

What drugs are being tested in NCT01231737?

Interventions in NCT01231737: prulifloxacin.

What condition does NCT01231737 study?

NCT01231737 studies Urinary Tract Infection.

Is NCT01231737 still recruiting?

NCT01231737 is currently status unknown. Last updated 29 October 2010.

Last reviewed 2010-10-29 · How we verify

NCT01231737

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of Prulifloxacin vs Phosphomycin in the Prophylasy of Urinary Tract Infection

Status unknown Phase 2 Last updated 29 October 2010

What this trial tests

Phase 2 trial testing prulifloxacin in Urinary Tract Infection in 96 participants. Status unknown.

Timeline

1 November 2010

Primary endpoint
1 February 2011

1 February 2012

Quick facts

Lead sponsor	University Of Perugia
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	96
Start date	1 November 2010
Primary completion	1 February 2011
Estimated completion	1 February 2012

Drugs / interventions tested

prulifloxacin — full drug profile →

Conditions studied

Urinary Tract Infection — all drugs for Urinary Tract Infection →

Sponsor

University Of Perugia

Who can join

Adults 18 to 75, female only, with Urinary Tract Infection. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

number of urinary tract infection episodes during prophylaxis
Time frame: 3 months

Sponsor's own description

Epidemiological studies showed that 20-30% of patients with uncomplicated urinary tract infections risked recurrent infection. Urinary tract infection causes marked discomfort for the patient, has a negative impact upon quality of life, and is associated with high social and health costs in terms of specialist appointments, laboratory and instrumental tests and prescriptions . Although diverse cycles of antibiotic therapy and prophylaxis have been proposed, doubts persist about the most efficacious pharmacological agents, duration of prophylaxis , the incidence of adverse effects and relapse when antibiotic therapy is suspended. Aims of the study: 1. To compare the efficacy of two prophylactic schedules (Prulifloxacin vs Phosphomycin): * in reducing the number of urinary tract infection episodes during prophylaxis * in reducing the number of urinary tract infection episodes after prophylaxis * in improving the patient's quality of life . 2. To assess : * Tolerability of antibiotic prophylaxis * The incidence of resistance to antibiotic therapy

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Urinary Tract Infection

Currently open trials in the same condition.

NCT07239219 — The Impact of Irrisept in Reducing Urinary Tract Infection During Urethral Catheter Removal. · NA · recruiting
NCT06896643 — Urinary Infection and Colonization in Bone Procedures · recruiting
NCT06689176 — Chlorhexidine Antiseptic Irrigation of the Bowel Segment During Radical Cystectomy and Urinary Diversion · NA · recruiting
NCT06613503 — Effectiveness of the AI-Supporter in Reducing Urinary Tract Infections · NA · recruiting

Other University Of Perugia trials

Trials by the same sponsor.

NCT05912894 — Anatomical Variation in Rouvière's Sulcus · not yet recruiting
NCT06544343 — Integration of Remote Monitoring in the Management of Chronic Immunosuppressive Therapy · NA · recruiting
NCT06398145 — D-chiro-inositol and AUB · Phase 2 · not yet recruiting
NCT07288632 — Effects of Genomic Profiles on Thromboembolic Risk in Patients With Locally Advanced or Metastatic Non-small-cell Lung C · recruiting
NCT06246604 — Screening for Deep Vein Thrombosis in Intensive Care · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01231737 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Of Perugia
Last refreshed: 29 October 2010

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01231737.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing